Sanjiv Patel
President and CEO
Relay Therapeutics
Sanjiv Patel brings to Relay Therapeutics more than 20 years of life sciences industry experience. Prior to Relay Therapeutics, Sanjiv was at Allergan for more than a decade, and played a key part in Allergan’s sustained growth and value creation over that period. Sanjiv held roles of increased responsibility, including leading global strategic marketing for all franchises and general management of Allergan’s fastest growth geographic region, the emerging markets. Sanjiv was most recently part of Allergan’s executive team as chief strategy officer, where he was at the center of some of the industry’s largest transactions. His work with the senior leadership team of Allergan defined its long-term objectives and strategy, including divestment and integration planning activities.
Prior to Allergan, Sanjiv was a management consultant at Boston Consulting Group in London and he started his career as a surgeon in the U.K.’s National Health Service.
Sanjiv holds an MBA from INSEAD, MBBS from the University of London and a M.A. in neurosciences from Cambridge University.
Don Bergstrom
President, R&D
Relay Therapeutics
As President, R&D, Don Bergstrom oversees Relay Therapeutics’ research and development efforts and shapes the Company’s portfolio of transformative medicines based on an understanding of protein motion. Prior to Relay Therapeutics, Don was chief medical officer at Mersana Therapeutics, where he oversaw the non-clinical and early clinical development of the first two products from Mersana’s proprietary antibody-drug conjugate platform. Prior to Mersana, he held leadership roles in translational medicine and early clinical development at Sanofi and Merck. Over his career in industry, Don has been a scientific leader on more than 15 successful IND applications and the development of five marketed drugs. Don sits on the Board of Directors of Fusion Pharmaceuticals and Cellectis.
Don holds an M.D. from the University of Washington, Seattle and a Ph.D. from the Fred Hutchinson Cancer Research Center, where he also completed post-doctoral training. He was a resident in clinical pathology at the University of Washington.
Pete Rahmer
Chief Corporate Development Officer
Relay Therapeutics
As Chief Corporate Development Officer, Pete Rahmer leads business development, corporate strategy, investor relations and external communications. Prior to Relay Therapeutics, Pete was the founder and managing partner of Endurance Advisors, a biotech-focused investor relations and capital markets advisory firm. Prior to Endurance, he was a managing director at the Trout Group and headed the firm’s West Coast practice. Earlier in his career, Pete was part of Thomson Financial’s Biotechnology Capital Markets Intelligence team.
Over the past 17 years, Pete has advised more than 50 companies in capital raising, strategy and investor relations, helping clients raise over $3 billion through capital market offerings over his tenure.
Pete holds a B.A. in economics from St. Lawrence University and an MBA from the Rochester Institute of Technology.